Vertex Pharmaceuticals | VRTX

Stock Price
392.81
Daily Change
-3.61 -0.91%
Monthly
-6.58%
Yearly
13.86%
Q2 Forecast
410.03
Peers Price Chg Day Year Date
ABBV AbbVie 162.81 1.43 0.89% 5.92% Apr/30
ACAD Acadia Pharmaceuticals 16.70 -0.40 -2.34% -23.22% Apr/30
AGIO Agios Pharmaceuticals 32.50 -0.26 -0.79% 40.15% Apr/30
ALNY Alnylam Pharmaceuticals 143.84 -3.52 -2.39% -28.75% Apr/30
AMGN Amgen 274.02 -2.37 -0.86% 14.70% Apr/30
ARWR Arrowhead Research 22.60 -0.53 -2.29% -36.73% Apr/30
BIIB Biogen 215.20 -0.12 -0.05% -30.83% Apr/30
BMRN BioMarin Pharmaceutical 80.76 -1.37 -1.67% -16.73% Apr/30
BMY Bristol-Myers Squibb 43.99 -0.62 -1.39% -35.69% Apr/30
GILD Gilead Sciences 65.20 -0.61 -0.93% -19.92% Apr/30
INCY Incyte 52.02 -0.50 -0.94% -30.96% Apr/30
INSM Insmed 24.69 -0.31 -1.24% 22.41% Apr/30
IONS Ionis Pharmaceuticals 41.24 -0.75 -1.79% 15.58% Apr/30
JNJ J&J 144.62 -2.15 -1.46% -11.60% Apr/30
MRK Merck 129.00 -0.70 -0.54% 10.88% Apr/30
MRNA Moderna 110.42 -1.17 -1.05% -17.23% Apr/30
NBIX Neurocrine Biosciences 137.54 -1.41 -1.01% 32.22% Apr/30
NOVN Novartis 89.05 0.18 0.20% -3.44% Apr/30
PFE Pfizer 25.60 0.05 0.20% -34.71% Apr/30
PTCT PTC Therapeutics 32.15 0.01 0.03% -41.73% Apr/30
RARE Ultragenyx Pharmaceutical 42.51 -1.51 -3.43% -3.45% Apr/30
REGN Regeneron Pharmaceuticals 891.32 -0.15 -0.02% 10.49% Apr/30
ROG Roche Holding 220.60 -0.60 -0.27% -21.40% Apr/30
SAN Sanofi 93.08 1.24 1.35% -4.21% Apr/30
SRPT Sarepta Therapeutics 126.54 -2.26 -1.75% 1.14% Apr/30
UTHR United Therapeutics 234.19 -4.07 -1.71% 0.90% Apr/30
VRTX Vertex Pharmaceuticals 392.81 -3.61 -0.91% 13.86% Apr/30

Indexes Price Day Year Date
US500 5025 -80.48 -1.57% 20.56% Apr/30
USND 15658 -325.26 -2.04% 28.21% Apr/30
US400 2861 -51.11 -1.76% 14.90% Apr/30
US100 17373 -342.03 -1.92% 31.30% Apr/30

Vertex Pharmaceuticals traded at $392.81 this Tuesday April 30th, decreasing $3.61 or 0.91 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 6.58 percent. Over the last 12 months, its price rose by 13.86 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 410.03 by the end of this quarter and at 386.98 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.